Phio Pharmaceuticals Corp.
PHIO
$1.98
-$0.16-7.48%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 985.00K | 644.00K | -- | 1.15M | 1.01M |
| Gross Profit | -985.00K | -644.00K | -- | -1.15M | -1.01M |
| SG&A Expenses | 689.00K | 946.00K | 1.05M | 1.06M | 766.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.67M | 1.59M | 1.91M | 2.21M | 1.77M |
| Operating Income | -1.67M | -1.59M | -1.91M | -2.21M | -1.77M |
| Income Before Tax | -1.63M | -1.52M | -1.85M | -2.15M | -1.90M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.63M | -1.52M | -1.85M | -2.15M | -1.90M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.63M | -1.52M | -1.85M | -2.15M | -1.90M |
| EBIT | -1.67M | -1.59M | -1.91M | -2.21M | -1.77M |
| EBITDA | -1.67M | -1.59M | -1.91M | -2.21M | -1.76M |
| EPS Basic | -1.43 | -1.54 | -3.62 | -4.23 | -5.67 |
| Normalized Basic EPS | -0.89 | -0.96 | -2.26 | -2.65 | -3.31 |
| EPS Diluted | -1.43 | -1.54 | -3.62 | -4.23 | -5.67 |
| Normalized Diluted EPS | -0.89 | -0.96 | -2.26 | -2.65 | -3.31 |
| Average Basic Shares Outstanding | 1.14M | 990.00K | 510.20K | 508.90K | 334.40K |
| Average Diluted Shares Outstanding | 1.14M | 990.00K | 510.20K | 508.90K | 334.40K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |